Literature DB >> 16940427

Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

Cyril Fauriat1, Sylvaine Just-Landi, Françoise Mallet, Christine Arnoulet, Danielle Sainty, Daniel Olive, Regis T Costello.   

Abstract

Natural killer (NK) cells play an important role in tumor-cell clearance, particularly against leukemia, as shown by killer cell inhibitory receptor (KIR)-mismatched allogeneic stem cell transplantation. Analysis of in vitro IL-2-expanded NK cells from patients with myelocytic/monocytic acute myeloid leukemia (AML-NK cells) has revealed poor cytolytic functions because of deficient expression of pivotal activation molecules-the natural cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46. To exclude the possibility that this observation was caused by the in vitro amplification of a small NCR(dull) population, we analyzed the AML-NK phenotype directly, without any in vitro expansion. We first confirmed that the NCR(dull) phenotype was not an in vitro artifact. Moreover, analysis of a large population of AML patients allowed us to demonstrate that phenotype was not restricted to a French-American-British (FAB) subtype and was not associated with a particular cytogenetic abnormality. Our longitudinal study of AML patients showed that the NCR(dull) phenotype was acquired during leukemia development because we observed its complete (for NKp46) or partial (for NKp30) reversibility in patients achieving complete remission (CR). Reversibility of the NCR(dull) phenotype after CR suggested that leukemia cells might be involved in NCR down-regulation. In agreement with this hypothesis, direct contact between leukemic blasts and NK cells (but not leukemia-cell supernatants) induced loss or decrease in NKp30 and NKp46 expression while impeding NKp44 induction by IL-2. We excluded the major implication of TGF-beta in NCR down-regulation. Although the clinical antitumor value of NK cells is clearly demonstrated in allogeneic stem cell transplantation, the role of NK cells in autologous transplantation is not proved. Interestingly, we observed a correlation between the NCR(dull) phenotype and poor survival in AML patients, suggesting that NK-deficient activation caused by NCR down-regulation could play a role in patient outcome. The prognostic value of NCR expression is discussed, and pathophysiologic implication of the NCR phenotype will be further investigated in a larger study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940427     DOI: 10.1182/blood-2005-08-027979

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  145 in total

1.  IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.

Authors:  Margherita Boieri; Aina Ulvmoen; Amanda Sudworth; Clare Lendrem; Matthew Collin; Anne M Dickinson; Lise Kveberg; Marit Inngjerdingen
Journal:  Oncoimmunology       Date:  2017-01-17       Impact factor: 8.110

2.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

3.  Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands.

Authors:  Julia Herrmann; Hannah Berberich; Jessica Hartmann; Steffen Beyer; Karen Davies; Joachim Koch
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

Review 4.  Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2012-12-28

5.  The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Authors:  Alexander Hallner; Elin Bernson; Brwa Ali Hussein; Frida Ewald Sander; Mats Brune; Johan Aurelius; Anna Martner; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Blood       Date:  2019-01-15       Impact factor: 22.113

6.  B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.

Authors:  Ming-Ru Wu; Tong Zhang; Albert T Gacerez; Tiffany A Coupet; Leslie R DeMars; Charles L Sentman
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

7.  Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.

Authors:  Jeffrey E Rubnitz; Patrick Campbell; Yinmei Zhou; John T Sandlund; Sima Jeha; Raul C Ribeiro; Hiroto Inaba; Deepa Bhojwani; Mary V Relling; Scott C Howard; Dario Campana; Ching-Hon Pui
Journal:  Cancer       Date:  2013-03-01       Impact factor: 6.860

8.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Authors:  Fernando Concha-Benavente; Benjamin Kansy; Jessica Moskovitz; Jennifer Moy; Uma Chandran; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2018-10-03       Impact factor: 11.151

9.  Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.

Authors:  Conor J Kearney; Kelly M Ramsbottom; Ilia Voskoboinik; Phillip K Darcy; Jane Oliaro
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

10.  Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML.

Authors:  Nathaniel J Buteyn; Ramasamy Santhanam; Giovanna Merchand-Reyes; Rakesh A Murugesan; Gino M Dettorre; John C Byrd; Anasuya Sarkar; Sumithira Vasu; Bethany L Mundy-Bosse; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Immunol       Date:  2020-02-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.